Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameKeymed Bio-B
Stock Code02162
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities專注於自主發現及開發自體免疫及腫瘤治療領域的創新生物療法,核心產品CM310(IL-4Rα抗體)用於治療多種過敏性疾病,管線包括八種候選藥物,其中五種為臨床階段候選藥物。
Listing Date2021-07-08
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)四川省成都天府國際生物城生物城中路18號D2棟
Business Address (Hong Kong)香港金鐘道力寶中心2座1701室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitekeymedbio.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 53.30 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 26,650
Par ValueTo be extracted
Offer Period2021-06-25 to 2021-06-30
Global Offering Shares58,264,500 shares
HK Public Offer Shares (Initial)5,827,000 shares (10.0%)
Public Offer Lots (Initial)11,654lots (Pool A5,827lots,Pool B5,827lots)
International Placing Shares (Initial)52,437,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO270,996,066 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share47.5%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,105,497,850

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 26,650
2 lots 1,000 HK$ 53,300
3 lots 1,500 HK$ 79,950
4 lots 2,000 HK$ 106,600
5 lots 2,500 HK$ 133,250
6 lots 3,000 HK$ 159,900
7 lots 3,500 HK$ 186,550
8 lots 4,000 HK$ 213,200
9 lots 4,500 HK$ 239,850
10 lots 5,000 HK$ 266,500
12 lots 6,000 HK$ 319,800
14 lots 7,000 HK$ 373,100
16 lots 8,000 HK$ 426,400
18 lots 9,000 HK$ 479,700
20 lots 10,000 HK$ 533,000
30 lots 15,000 HK$ 799,500
40 lots 20,000 HK$ 1,066,000
50 lots 25,000 HK$ 1,332,500
60 lots 30,000 HK$ 1,599,000
70 lots 35,000 HK$ 1,865,500
80 lots 40,000 HK$ 2,132,000
90 lots 45,000 HK$ 2,398,500
100 lots 50,000 HK$ 2,665,000
120 lots 60,000 HK$ 3,198,000
140 lots 70,000 HK$ 3,731,000
160 lots 80,000 HK$ 4,264,000
180 lots 90,000 HK$ 4,797,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
200 lots 100,000 HK$ 5,330,000
300 lots 150,000 HK$ 7,995,000
400 lots 200,000 HK$ 10,660,000
500 lots 250,000 HK$ 13,325,000
600 lots 300,000 HK$ 15,990,000
700 lots 350,000 HK$ 18,655,000
800 lots 400,000 HK$ 21,320,000
900 lots 450,000 HK$ 23,985,000
1,000 lots 500,000 HK$ 26,650,000
1,200 lots 600,000 HK$ 31,980,000
1,400 lots 700,000 HK$ 37,310,000
1,600 lots 800,000 HK$ 42,640,000
1,800 lots 900,000 HK$ 47,970,000
2,000 lots 1,000,000 HK$ 53,300,000
3,000 lots 1,500,000 HK$ 79,950,000
4,000 lots 2,000,000 HK$ 106,600,000
5,000 lots 2,500,000 HK$ 133,250,000
5,827 lots 2,913,500 HK$ 155,289,550

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 20.42B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 14,444,090,317
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损人民币818.8百万元
Period-End Cash Balance人民币199.4百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Revenue 15,64541,190
Administrative expenses -15,158-21,548
Net finance costs -5,677-14,309
Profit before tax -167,512-818,848
Income tax expense 00
Profit for the year -167,512-818,848
Profit attributable to owners -167,512-818,583
Balance Sheet
Item 20192020
Cash and cash equivalents 432,608199,409
Inventories 3,3066,846
Total current assets 518,405380,917
Total assets 658,578529,945
Total current liabilities 71,59080,240
Total liabilities 934,5331,624,748
Total equity -275,955-1,094,803
Equity attributable to owners -275,955-1,094,538
Cash Flow Statement
Item 20192020
Net cash from operating activities -68,379-119,361
Net cash from investing activities -58,020-113,067
Net cash from financing activities 505,0667,397
Net increase in cash 378,667-225,031
Depreciation of PP&E 8,13613,894
Depreciation of right-of-use assets 4,1635,079
Amortisation of intangible assets 019
Purchase of PP&E -62,264-19,806
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 68.0
First Day OpenHK$ 78.0
First Day Change27.58%
First Day Volume42544600.0
First Day Turnover3004370000.0
Use of Proceeds
1、約60%,或1765.20百萬港元,于未來三至五年內,將主要用于核心及主要產品的研發及商業化; 2、約15%,或441.30百萬港元,將用于我們其他在研產品的臨床前評估及臨床開發; 3、約15%,或441.30百萬港元,將用于我們新生產及研發設施的租賃付款,及購買機械及設備; 4、約10%,或294.20百萬港元將用于我們的一般企業及營運資金用途。

Underwriting Syndicate

Joint Sponsors (3)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Bookrunners (4)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Joint Lead Managers (4)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Aranda Investments Pte. Ltd. 116,433,850 HKD — 3.75% — 6 months 2022-01-08
2 Boyu Capital Opportunities Master Fund 77,631,450 HKD — 2.50% — 6 months 2022-01-08
3 Double Joy Ventures Limited 77,631,450 HKD — 2.50% — 6 months 2022-01-08
4 Hillhouse Funds 116,433,850 HKD — 3.75% — 6 months 2022-01-08
5 Hudson Bay Master Fund LTD 38,802,400 HKD — 1.25% — 6 months 2022-01-08
6 Invesco Advisers, Inc. 310,525,800 HKD — 10.00% — 6 months 2022-01-08
7 Janchor Partners Pan-Asian Master Fund 38,802,400 HKD — 1.25% — 6 months 2022-01-08
8 Lake Bleu Prime Healthcare Master Fund Limited 77,631,450 HKD — 2.50% — 6 months 2022-01-08
9 LAV Fund VI 77,631,450 HKD — 2.50% — 6 months 2022-01-08
10 Octagon Investments Master Fund LP 38,802,400 HKD — 1.25% — 6 months 2022-01-08
11 Sage Partners Master Fund 38,802,400 HKD — 1.25% — 6 months 2022-01-08
12 Springhill Master Fund Limited 38,802,400 HKD — 1.25% — 6 months 2022-01-08
13 UBS Asset Management (Singapore) Ltd. 310,525,800 HKD — 10.00% — 6 months 2022-01-08
14 Yi Fang Da Sirius Inv. Limited 38,802,400 HKD — 1.25% — 6 months 2022-01-08
15 佳曦控股有限公司 77,631,450 HKD — 2.50% — 6 months 2022-01-08

Directors & Management

PositionChinese nameEnglish Name
ChairmanBo CHEN—
Company Secretary張延榮、王承鏱—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東為Moonshot(由陳博士控制),緊隨全球發售後持股28.71%;高瓴資本管理有限公司通過HH KNY Holdings Limited持股9.56%;Eagle Hero持股6.63%。
About this page

This page shows Keymed Bio-B (02162) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect